Cognition After Lowering LDL-Cholesterol With Evolocumab

Area of Science:

• Cardiovascular Medicine
• Neuroscience
• Pharmacology

Background:

• The EBBINGHAUS trial investigated the cognitive effects of evolocumab in patients within the FOURIER trial.
• Evolocumab is a PCSK9 inhibitor used alongside statin therapy for cardiovascular risk reduction.

Purpose of the Study:

• To assess the impact of evolocumab on patient-reported cognitive function in individuals with atherosclerotic cardiovascular disease.
• To analyze cognitive changes based on treatment arm and achieved low-density lipoprotein cholesterol (LDL-C) levels.

Main Methods:

• A randomized, double-blind, placebo-controlled trial (FOURIER) involving 22,655 patients.
• Patients completed the Everyday Cognition (ECog) scale, comparing cognitive function at the end of the trial to the beginning.
• Cognitive scores were analyzed in relation to evolocumab treatment and achieved LDL-C levels.

Main Results:

• No significant difference in reported cognitive decline (ECog score ≥2) between the evolocumab and placebo groups (3.7% vs. 3.6%).
• Cognitive decline rates were similar across memory and executive function subdomains.
• Patients achieving very low LDL-C (<20 mg/dl) showed no increased cognitive decline compared to those with higher LDL-C levels (≥100 mg/dl).

Conclusions:

• Adding evolocumab to statin therapy does not negatively impact patient-reported cognitive function.
• The cognitive safety of evolocumab is confirmed, even with intensive LDL-C lowering.
• These findings support the use of evolocumab in managing cardiovascular risk without compromising cognitive health.